WCLC 2025 - Posters & ePosters-P2.10.13 Sunvozertinib Combined With Bevacizumab in Previously Treated Advanced NSCLC With EGFR Exon 20 Insertion Mutations

Pdf Summary

This study investigates the efficacy and safety of sunvozertinib combined with bevacizumab in treating advanced non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins) who were previously treated. Sunvozertinib is an irreversible EGFR inhibitor selective for exon20ins mutations, approved in China and the U.S. after progression on platinum-based chemotherapy. Bevacizumab is an antiangiogenic agent hypothesized to enhance sunvozertinib’s antitumor effect.<br /><br />Preclinical evaluation using patient-derived xenograft (PDX) models demonstrated that the combination led to greater tumor shrinkage, significantly decreased tumor microvessel density, and stronger inhibition of downstream signaling (pS6), compared to either drug alone, without notable body weight changes.<br /><br />In the ongoing phase 2 WU-KONG29 clinical trial, 14 patients with advanced NSCLC harboring EGFR exon20ins received sunvozertinib 300 mg daily plus bevacizumab 15 mg/kg every three weeks. Patients had a median age of 55.5 years; 42.9% had baseline brain metastases. Most patients had prior chemotherapy, immunotherapy, or antiangiogenic therapy.<br /><br />Key clinical outcomes included a confirmed objective response rate (cORR) of 50% and a disease control rate (DCR) of 100%. In patients with brain metastases, cORR was also 50%. Tumor shrinkage was observed in 85.7% of patients. Median progression-free survival (PFS) was 16.4 months, and median duration of response was 19.1 months, with ongoing responses at data cutoff (June 23, 2025).<br /><br />The combination therapy was generally well tolerated; 15.8% discontinued due to treatment-related adverse events (mostly mild to moderate), including diarrhea, vomiting, rash, stomatitis, weight loss, and proteinuria. No unexpected safety issues emerged beyond those known for each drug.<br /><br />In conclusion, sunvozertinib plus bevacizumab shows promising and durable antitumor activity with a manageable safety profile in previously treated NSCLC patients with EGFR exon20ins, supporting its potential as a clinical treatment option in this population.

Asset Subtitle

Yongfeng Yu

Meta Tag

Speaker Yongfeng Yu

Topic Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

Keywords

Sunvozertinib

Bevacizumab

EGFR exon 20 insertion mutations

Non-small cell lung cancer

Advanced NSCLC

Combination therapy

Objective response rate

Progression-free survival

Patient-derived xenograft models

Treatment-related adverse events